Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | HTT | P42858 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15463039 | 1.00 | HPGD (0.59) | HPGDSMN1; SMN2ALDH1A1HTTKMT2A | |
| SCHEMBL3471747 | 1.00 | HPGD (0.59) | HPGDSMN1; SMN2ALDH1A1HTTKMT2A | |
| SCHEMBL22824610 | 0.90 | ALDH1A1 (0.54) | HPGDSMN1; SMN2ALDH1A1HTTKMT2A | |
| SCHEMBL30393930 | 0.89 | ALDH1A1 (0.52) | HPGDSMN1; SMN2ALDH1A1HTTKMT2A | |
| SCHEMBL10050296 | 0.89 | ALDH1A1 (0.52) | HPGDSMN1; SMN2ALDH1A1HTTKMT2A | |
| SCHEMBL7120261 | 0.87 | ALDH1A1 (0.51) | HPGDSMN1; SMN2ALDH1A1HTTKMT2A | |
| SCHEMBL7120256 | 0.87 | ALDH1A1 (0.51) | HPGDSMN1; SMN2ALDH1A1HTTKMT2A | |
| SCHEMBL2446290 | 0.87 | ALDH1A1 (0.75) | HPGDSMN1; SMN2ALDH1A1HTTKMT2A | |
| SCHEMBL12120526 | 0.87 | HSD17B10 (0.75) | HPGDSMN1; SMN2ALDH1A1HTTKMT2A | |
| SCHEMBL2446293 | 0.87 | ALDH1A1 (0.75) | HPGDSMN1; SMN2ALDH1A1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350030-B9 | ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2016-10-26 | — | — | EP | disclosed |
| EP-2350030-B1 | ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2016-04-20 | — | — | EP | disclosed |
| US-8883809-B2 | Isoxazole/isoxazoline/combretastatin linked dihydroquinazolinone hybrids as potential anticancer agents and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-11-11 | — | — | US | disclosed |
| US-20120283439-A1 | ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Redearch (IN) | 2012-11-08 | — | — | US | disclosed |
| WO-2010074776-A2 | COMPOUNDS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010058417-A1 | ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283439-A1 | ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | NDUFAF1, TOP1, COX4I1 | HPGD 1008/4885SMN1; SMN2 4334/4885ALDH1A1 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.